Idecabtagene vicleucel (Abecma®) for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior therapies

Rothschedl, E. and Grössmann, N. (2024): Idecabtagene vicleucel (Abecma®) for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior therapies. Fact Sheet Nr. 162.

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
155kB

Item Type:	Horizon Scanning of Medicines
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WH Hemic and lymphatic systems
Language:	English
Series Name:	Fact Sheet Nr. 162
Deposited on:	12 Feb 2024 17:01
Last Modified:	12 Feb 2024 17:01

Repository Staff Only: item control page